Epigenetic screening to resensitize resistant Diffuse Large B-Cell Lymphoma (DLBCL) cell lines

Project Details


Drug screening investigating the ability of epigenetic inhibitors to modulate the chromatin structure and reprogram therapy-resistant cancer cells into sensitive ones. Our screening tested 60 epigenetic compounds on four R-CHOP resistant DLBCL cell lines.
Effective start/end date04/08/201411/12/2019


  • 1 Invited talk

Drug resistance and DLBCL: an epigenetic reprogramming story

Julia Casado Cuervo (Speaker)

13 Dec 2016

Activity: Talk or presentation typesInvited talk